Literature DB >> 11777552

Heightened intrathecal release of axonal cytoskeletal proteins in multiple sclerosis is associated with progressive disease and clinical disability.

Y K Semra1, O A Seidi, M K Sharief.   

Abstract

The pathologic basis of disease progression in multiple sclerosis (MS) is thought to involve axonal degeneration, which contributes to the accumulation of neurological disability. Recent reports suggest that intrathecal concentrations of the neurofilament protein in relapsing remitting MS correlate with disease activity and the degree of disability. We sought to investigate the intrathecal levels of other cytoskeletal components of axons, primarily actin, tubulin and the light subunit of neurofilament (NFL) in patients with progressive MS and relevant controls and correlate results with clinical parameters of disease severity. Cerebrospinal fluid (CSF) concentrations of actin, tubulin and NFL were significantly increased in MS patients when compared to corresponding levels in patients with other inflammatory or non-inflammatory neurological diseases. Moreover, the intrathecal release of actin and tubulin, and to a lesser extent NFL, was significantly more marked in patients with primary and secondary progressive MS when compared to patients with relapsing remitting disease and was correlated with clinical disability. Our findings suggest that progressive MS is associated with the heightened intrathecal release of axonal cytoskeletal proteins, and that CSF actin, tubulin and NFL are reliable markers of axonal damage.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11777552     DOI: 10.1016/s0165-5728(01)00455-6

Source DB:  PubMed          Journal:  J Neuroimmunol        ISSN: 0165-5728            Impact factor:   3.478


  32 in total

1.  Elevated intrathecal antibodies against the medium neurofilament subunit in multiple sclerosis.

Authors:  Ales Bartos; Lenka Fialová; Jirina Soukupová; Jaromír Kukal; Ivan Malbohan; Jirí Pit'ha
Journal:  J Neurol       Date:  2007-02-14       Impact factor: 4.849

Review 2.  Blood Biomarkers as Outcome Measures in Inflammatory Neurologic Diseases.

Authors:  Nabil K El Ayoubi; Samia J Khoury
Journal:  Neurotherapeutics       Date:  2017-01       Impact factor: 7.620

3.  Cytoskeletal proteins in the cerebrospinal fluid as biomarker of multiple sclerosis.

Authors:  Roberto Madeddu; Cristiano Farace; Paola Tolu; Giuliana Solinas; Yolande Asara; Maria Alessandra Sotgiu; Lucia Gemma Delogu; Jose Carlos Prados; Stefano Sotgiu; Andrea Montella
Journal:  Neurol Sci       Date:  2012-02-24       Impact factor: 3.307

4.  Gelsolin decreases actin toxicity and inflammation in murine multiple sclerosis.

Authors:  Kevin Li-ChunHsieh; Stefan Schob; Matthias W G Zeller; Benjamin Pulli; Muhammad Ali; Cuihua Wang; Terry Ting-Yu Chiou; Yuk-Ming Tsang; Po-Shun Lee; Thomas P Stossel; John W Chen
Journal:  J Neuroimmunol       Date:  2015-08-09       Impact factor: 3.478

5.  Axonal damage accumulates in the progressive phase of multiple sclerosis: three year follow up study.

Authors:  A Petzold; M J Eikelenboom; G Keir; D Grant; R H C Lazeron; C H Polman; B M J Uitdehaag; E J Thompson; G Giovannoni
Journal:  J Neurol Neurosurg Psychiatry       Date:  2005-02       Impact factor: 10.154

6.  Glial fibrillary acidic protein: a potential biomarker for progression in multiple sclerosis.

Authors:  M Axelsson; C Malmeström; S Nilsson; S Haghighi; L Rosengren; J Lycke
Journal:  J Neurol       Date:  2011-01-01       Impact factor: 4.849

7.  Cerebrospinal fluid in multiple sclerosis.

Authors:  Kottil W Rammohan
Journal:  Ann Indian Acad Neurol       Date:  2009-10       Impact factor: 1.383

8.  Hypogelsolinemia, a disorder of the extracellular actin scavenger system, in patients with multiple sclerosis.

Authors:  Alina Kułakowska; Nicholas J Ciccarelli; Qi Wen; Barbara Mroczko; Wiesław Drozdowski; Maciej Szmitkowski; Paul A Janmey; Robert Bucki
Journal:  BMC Neurol       Date:  2010-11-01       Impact factor: 2.474

Review 9.  Disease biomarkers in multiple sclerosis: potential for use in therapeutic decision making.

Authors:  Violaine K Harris; Saud A Sadiq
Journal:  Mol Diagn Ther       Date:  2009       Impact factor: 4.074

10.  Vitamin D-binding protein in cerebrospinal fluid is associated with multiple sclerosis progression.

Authors:  Mingchong Yang; Zhaoyu Qin; Yanyan Zhu; Yun Li; Yanjiang Qin; Yongsheng Jing; Shilian Liu
Journal:  Mol Neurobiol       Date:  2013-01-22       Impact factor: 5.590

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.